Novo Nordisk A/S (NVO) just went through the corporate governance equivalent of a controlled demolition, and the new chairman wants everyone to know he's got things under control. Lars Rebien Sorensen, freshly installed in the top seat, is promising to beef up the board's pharmaceutical chops while trying to calm nerves about a foundation-led power grab that has minority shareholders less than thrilled.
On Friday, the company held an Extraordinary General Meeting to elect new board members, and it was quite the changing of the guard. Former chairman Helge Lund, vice chair Henrik Poulsen, and five other directors—Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay—all stepped down. That's seven board members out the door in one swoop.
A Foundation's Grip Tightens
In came Sorensen as chair, Cees de Jong as vice chair, and new board members Britt Meelby Jensen and Stephan Engels. Simple enough, except for one small detail: this restructuring handed the Novo Nordisk Foundation a whopping 77% of the company's voting rights, despite the foundation holding only about 28% of actual share capital.
That kind of lopsided power structure has critics asking pointed questions about governance stability and accountability. The extraordinary meeting essentially finalized a setup where the foundation calls the shots, and minority investors get to watch from the sidelines. Over 90% of shareholders voted in favor, but a vocal minority either abstained or raised red flags about concentrated control.
What makes this particularly interesting—or concerning, depending on your perspective—is that Sorensen now chairs both the company and the foundation itself. It's a dual role the company has never seen before, and it's sparked worries that too much authority is sitting in one person's lap.
Short-Term Chair With Long-Term Plans
Sorensen pushed back against those concerns, emphasizing that his tenure will be brief and transitional. He's positioning himself as the steady hand needed to navigate a turbulent moment, not a permanent fixture consolidating power indefinitely.
The board overhaul came on the heels of last month's sudden departure of Lund and several independent directors who objected to how the foundation was handling governance. According to Sorensen, the foundation believed deeper changes were necessary to stabilize the company and support long-term growth amid rapid strategic shifts and leadership turnover.
His immediate priority? Adding directors with fresh pharmaceutical and over-the-counter experience. The timing isn't random—Novo Nordisk is accelerating its pivot toward a direct-to-consumer, cash-pay model, and the board needs people who understand that landscape.
Sorensen didn't mince words about the previous board's performance, either. He criticized the old guard for moving too slowly to address weakening results in the U.S. market. Last summer, he pushed hard to fast-track the appointment of new CEO Mike Doustdar, who's now overseeing a major round of global layoffs as part of the strategic overhaul.
M&A Miss And Market Struggles
The company also made an aggressive play for Metsera, an obesity drug maker that would have fit nicely into Novo Nordisk's portfolio. But Pfizer (PFE) swooped in and clinched the $10 billion deal, leaving Novo Nordisk empty-handed in what became a fierce bidding war.
Meanwhile, the stock isn't exactly inspiring confidence. Novo Nordisk shares were down 0.12% at $48.20 at the time of publication on Monday, trading near their 52-week low of $45.05. Investors are clearly taking a wait-and-see approach to the new leadership structure and strategic direction.
The foundation's argument is straightforward: radical times call for radical measures, and the company needed decisive action to course-correct. Critics counter that concentrating voting power and leadership roles undermines the independent oversight that public companies are supposed to maintain. Both sides have a point, which is why this governance fight matters beyond just one Danish pharmaceutical giant.
Sorensen insists his chairmanship is temporary and his focus is practical—get the right expertise on the board, support the new CEO's turnaround efforts, and position Novo Nordisk for whatever comes next in the rapidly evolving weight-loss and diabetes markets. Whether minority shareholders buy that explanation, or whether they'll continue raising governance alarms, remains to be seen.
